Cboe UK SEK

Infant Bacterial Therapeutics AB (publ) (IBTBS.XC)

Compare
0.0000 -109.0000 (-100.00%)
At close: July 23 at 9:00:00 PM GMT+1
Currency in SEK All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Operating Expense
153,550.0000
134,617.0000
65,808.0000
44,578.0000
71,918.0000
Operating Income
-153,550.0000
-134,617.0000
-65,808.0000
-44,578.0000
-71,918.0000
Net Non Operating Interest Income Expense
9,518.0000
11,549.0000
357.0000
-413.0000
-89.0000
Pretax Income
-144,032.0000
-123,068.0000
-65,451.0000
-44,991.0000
-72,007.0000
Net Income Common Stockholders
-144,032.0000
-123,068.0000
-65,451.0000
-44,991.0000
-72,007.0000
Diluted NI Available to Com Stockholders
-144,032.0000
-123,068.0000
-65,451.0000
-44,991.0000
-72,007.0000
Basic EPS
-10.75
-9.95
-5.83
-4.01
-6.41
Diluted EPS
-10.75
-9.95
-5.83
-4.01
-6.41
Basic Average Shares
13,485.0980
12,364.6140
11,226.1840
11,226.1840
11,226.1840
Diluted Average Shares
13,485.0980
12,364.6140
11,226.1840
11,226.1840
11,226.1840
Total Operating Income as Reported
-153,549.0000
-134,617.0000
-65,808.0000
-44,578.0000
-71,918.0000
Total Expenses
153,550.0000
134,617.0000
65,808.0000
44,578.0000
71,918.0000
Net Income from Continuing & Discontinued Operation
-144,032.0000
-123,068.0000
-65,451.0000
-44,991.0000
-72,007.0000
Normalized Income
-144,032.0000
-123,068.0000
-65,451.0000
-44,991.0000
-72,007.0000
Interest Income
9,518.0000
11,549.0000
650.0000
--
214.0000
Interest Expense
--
--
293.0000
413.0000
303.0000
Net Interest Income
9,518.0000
11,549.0000
357.0000
-413.0000
-89.0000
EBIT
-144,032.0000
-123,068.0000
-65,158.0000
-44,578.0000
-71,704.0000
EBITDA
-143,216.0000
-122,252.0000
-64,342.0000
-43,762.0000
-70,888.0000
Reconciled Depreciation
816.0000
816.0000
816.0000
816.0000
816.0000
Net Income from Continuing Operation Net Minority Interest
-144,032.0000
-123,068.0000
-65,451.0000
-44,991.0000
-72,007.0000
Normalized EBITDA
-143,216.0000
-122,252.0000
-64,342.0000
-43,762.0000
-70,888.0000
12/31/2020 - 9/30/2019

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade